"A.O. - Policlinico Di Modena"
Welcome,         Profile    Billing    Logout  
 9 Trials 
9 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Conte, PierFranco
NCT00289263: Maintenance Chemotherapy in Metastatic Breast Cancer

Active, not recruiting
3
524
Europe
Paclitaxel
MANTA 1 Study Italian Collaborative Group, Bristol-Myers Squibb
Breast Cancer
 
10/03
A-Brave, NCT02926196 / 2016-000189-45: Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

Hourglass Apr 2021 - Sep 2021 : From A-Brave trial
Checkmark [VIRTUAL] Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial.
Active, not recruiting
3
474
Europe
MSB0010718C, Avelumab
Istituto Oncologico Veneto IRCCS, University of Padova, Dipartimento di scienze chirurgiche, Oncologiche e Gastroenterologiche
Triple Negative Breast Neoplasms
12/21
06/23
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Either Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Checkmark ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapy
Recruiting
3
800
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd.
Neoplasms, Breast
02/25
08/29
INSIGHT 2, NCT03940703: A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC

Checkmark [VIRTUAL] Tepotinib Plus an EGFR TKI in Patients with EGFR - mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
Checkmark [VIRTUAL] Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.
Checkmark [VIRTUAL] INSIGHT 2: Tepotinib + osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
Checkmark Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study
Checkmark INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
More
Recruiting
2
120
Europe, Japan, US, RoW
Tepotinib, Osimertinib, Tagrisso®
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Non-small Cell Lung Cancer
11/22
03/23
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Recruiting
2
384
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs
Fondazione per la Medicina Personalizzata, BMS Italia, Incyte Biosciences International Sàrl, Roche SpA, Pfizer S.r.l., Novartis Farma S.p.A, Takeda Italia Spa
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
04/24
08/24
NCT01134250: Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Recruiting
1/2
96
Europe
F16IL2 in combination with paclitaxel
Philogen S.p.A.
Solid Tumour,, Breast Cancer,, Metastatic Melanoma,, Non-small Cell Lung Cancer (NSCLC),
05/15
05/16
NCT04182516: Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors

Recruiting
1
100
Europe, US
NMS-03305293
Nerviano Medical Sciences
Advanced/Metastatic Solid Tumors
11/21
04/23
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Available
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 
METAMECH, NCT04625023: A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer

Recruiting
N/A
500
Europe
Observational
IFOM, The FIRC Institute of Molecular Oncology
Breast Cancer
07/26
12/26

Download Options